EGFR and colorectal carcinoma: An independent research group reported similar results, BRAF inhibition in BRAFm CRC triggered an EGFR-mediated rebound activation of the MAPK pathway, which can be blocked by concomitant administration of an anti-EGFR targeted agent [27••].